Attività
Vendite per attività
USD in Milioni | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
Autologous Tumor Infiltrating Lymphocytes
100,0
%
| 0 | nan % | 1 | 100,0 % | - |
Vendite per regione
USD in Milioni | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
United States
100,0
%
| 0 | nan % | 1 | 100,0 % | - |
Dirigenti
Dirigenti | Titolo | Età | Da |
---|---|---|---|
Frederick Vogt
CEO | Chief Executive Officer | 50 | 30/09/16 |
Director of Finance/CFO | 51 | 14/12/20 | |
Brian Shew
CTO | Chief Tech/Sci/R&D Officer | - | 01/07/21 |
Chief Tech/Sci/R&D Officer | 51 | 18/07/19 | |
Igor Bilinsky
COO | Chief Operating Officer | 51 | 15/03/21 |
Merrill McPeak
BRD | Director/Board Member | 88 | 20/07/11 |
Sara Pellegrino
IRC | Investor Relations Contact | - | - |
Tracy Winton
HRO | Human Resources Officer | - | 01/04/20 |
Raj K. Puri
PRN | Corporate Officer/Principal | - | 01/03/22 |
Jim Ziegler
PRN | Corporate Officer/Principal | - | 01/02/20 |
Amministratori
Amministratori | Titolo | Età | Da |
---|---|---|---|
Merrill McPeak
BRD | Director/Board Member | 88 | 20/07/11 |
Director/Board Member | 56 | 07/06/16 | |
Michael Weiser
BRD | Director/Board Member | 61 | 15/03/18 |
Wendy Yarno
BRD | Director/Board Member | 69 | 18/04/23 |
Ryan Maynard
BRD | Director/Board Member | 54 | 16/02/15 |
Iain Dukes
CHM | Chairman | 65 | 01/06/16 |
Director/Board Member | 52 | 10/06/19 |
Classe di azioni
Voto | Quantità | Flottante | Autocontrollo | Flottante totale | |
---|---|---|---|---|---|
Azione A | 0 | 2 842 158 | 0 | 0 | 92,59 % |
Azione B | 0 | 194 | 0 | 0 | |
Azione C | 1 | 279 832 722 | 259 105 707 ( 92,59 %) | 0 |
Coordinate società
Iovance Biotherapeutics, Inc.
825 Industrial Road Suite 400
94070, San Carlos
+650 260 7120
http://www.iovance.comSettore
Variaz. 1 gen. | Capi. | |
---|---|---|
-27,90% | 9,84 Mrd | |
-4,81% | 3,15 Mrd | |
-14,73% | 2,15 Mrd | |
-14,39% | 1,8 Mrd | |
+70,99% | 1,49 Mrd | |
+23,17% | 770 Mln | |
-2,18% | 762 Mln | |
+3,18% | 308 Mln | |
+6,63% | 210 Mln |